Related Experiment Videos
[Fundamental studies and clinical evaluation of PC-904 in urinary tract infection (author's transl)]
Abstract:
Measurement of MICs of PC-904, CBPC and GM against 135 strains of Pseudomonas aeruginosa isolated from patients with urinary tract infections was performed. Susceptibility to PC-904 of Pseudomonas aeruginosa was found to be 3 approximately 7 times more sensitive than that to CBPC and as same as that to GM with inoculum size of 10(8)/ml and 10(6)/ml. Serum level of PC-904 reached a peak of 38.5 microgram/ml 15 minutes after 0.5 g intravenous administration. Urinary recovery rate unit 6 hours after the administration was 12.5%. Overall clinical efficacy of 6 cases of acute simple cystitis and 3 cases of chronic complicated cystitis was judged to be 83.3% and 33.3% respectively by a criterion proposed by the UTI Committee in Japan.
Insights
PC-904 demonstrates potent activity against Pseudomonas aeruginosa, a common cause of urinary tract infections (UTIs). This new antibiotic shows promising efficacy in early clinical trials for cystitis.
Area of Science:
- Microbiology
- Pharmacology
- Clinical Medicine
Background:
- Pseudomonas aeruginosa is a significant pathogen in urinary tract infections (UTIs).
- Limited effective therapeutic options necessitate the development of new antimicrobial agents.
- Understanding the in vitro and in vivo activity of novel compounds is crucial.
Purpose of the Study:
- To evaluate the in vitro antimicrobial activity of PC-904 against Pseudomonas aeruginosa.
- To assess the pharmacokinetic profile of PC-904 following intravenous administration.
- To determine the clinical efficacy of PC-904 in patients with UTIs.
Main Methods:
- Minimum Inhibitory Concentrations (MICs) of PC-904, CBPC, and GM were determined for 135 Pseudomonas aeruginosa strains.
- Pharmacokinetic analysis included peak serum levels and urinary recovery rates after intravenous PC-904.
- Clinical efficacy was assessed in patients with acute simple and chronic complicated cystitis.
Main Results:
- PC-904 exhibited 3-7 times greater susceptibility than CBPC and comparable activity to GM against Pseudomonas aeruginosa.
- Peak serum levels of PC-904 reached 38.5 microgram/ml 15 minutes post-administration.
- Urinary recovery rate was 12.5% at 6 hours; clinical efficacy was 83.3% for acute simple cystitis and 33.3% for chronic complicated cystitis.
Conclusions:
- PC-904 demonstrates significant in vitro activity against Pseudomonas aeruginosa relevant to UTIs.
- The pharmacokinetic profile suggests adequate systemic and urinary concentrations.
- PC-904 shows potential clinical utility, particularly in acute simple cystitis.